Altered Tubulin Expression in Paclitaxel-Resistant Prostate Cancer Cells
Author Information
Author(s): S Ranganathan, CA Benetatos, PJ Colarusso, DW Dexter, GR Hudes
Primary Institution: Fox Chase Cancer Center
Hypothesis
The study investigates the role of beta-tubulin isotype composition in resistance to paclitaxel in human prostate carcinoma cells.
Conclusion
Paclitaxel-resistant prostate carcinoma cells exhibit increased levels of specific beta-tubulin isotypes, which may contribute to their resistance against the drug.
Supporting Evidence
- Pac-10 cells were fivefold resistant to paclitaxel compared to DU-145 cells.
- RT-PCR analysis showed ninefold higher levels of the PIII isotype in Pac-10 cells.
- Immunofluorescent staining revealed increased levels of alpha- and beta-tubulin in Pac-10 cells.
Takeaway
Some prostate cancer cells can become resistant to a drug called paclitaxel, and this study found that they change the types of tubulin proteins they use to help them survive the drug.
Methodology
The study involved selecting paclitaxel-resistant DU-145 cells and analyzing their beta-tubulin isotype composition through various assays including RT-PCR and western blot.
Want to read the original?
Access the complete publication on the publisher's website